Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. Co.'s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which Co. refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which Co. refers to as RAS Companion Inhibitors. Co.'s primary product candidate is the RAS Companion Inhibitor RMC-4630, designed as a selective inhibitor of SHP2, a central node in the RAS signaling pathway. The RVMD stock yearly return is shown above.
The yearly return on the RVMD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RVMD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|